Literature DB >> 21899827

Glucuronidation of the steroid enantiomers ent-17β-estradiol, ent-androsterone and ent-etiocholanolone by the human UDP-glucuronosyltransferases.

Nina Sneitz1, Kathiresan Krishnan, Douglas F Covey, Moshe Finel.   

Abstract

Steroids enantiomers are interesting compounds for detailed exploration of drug metabolizing enzymes, such as the UDP-glucuronosyltransferases (UGTs). We have now studied the glucuronidation of the enantiomers of estradiol, androsterone and etiocholanolone by the 19 human UGTs of subfamilies 1A, 2A and 2B. The results reveal that the pattern of human UGTs of subfamily 2B that glucuronidate ent-17β-estradiol, particularly 2B15 and 2B17, resembles the glucuronidation of epiestradiol (17α-estradiol) rather than 17β-estradiol, the main physiological estrogen. The UGTs of subfamilies 1A and 2A exhibit higher degree of regioselectivity than enantioselectivity in the conjugation of these estradiols, regardless of whether the activity is primarily toward the non-chiral site, 3-OH (UGT1A1, UGT1A3, UGT1A7, UGT1A8 and, above all, UGT1A10), or the 17-OH (UGT1A4). In the cases of etiocholanolone and androsterone, glucuronidation of the ent-androgens, like the conjugation of the natural androgens, is mainly catalyzed by UGTs of subfamilies 2A and 2B. Nevertheless, the glucuronidation of ent-etiocholanolone and ent-androsterone by both UGT2B7 and UGT2B17 differs considerably from their respective activity toward the corresponding endogenous androgens, whereas UGT2A1-catalyzed conjugation is much less affected by the stereochemistry differences. Kinetic analyses reveal that the K(m) value of UGT2A1 for ent-estradiol is much higher than the corresponding value in the other two high activity enzymes, UGT1A10 and UGT2B7. Taken together, the results highlight large enantioselectivity differences between individual UGTs, particularly those of subfamily 2B.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21899827      PMCID: PMC3234363          DOI: 10.1016/j.jsbmb.2011.08.008

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  18 in total

Review 1.  Structural and functional studies of UDP-glucuronosyltransferases.

Authors:  A Radominska-Pandya; P J Czernik; J M Little; E Battaglia; P I Mackenzie
Journal:  Drug Metab Rev       Date:  1999-11       Impact factor: 4.518

2.  Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism.

Authors:  Jenny Jakobsson; Lena Ekström; Nobuo Inotsume; Mats Garle; Mattias Lorentzon; Claes Ohlsson; Hyung-Keun Roh; Kjell Carlström; Anders Rane
Journal:  J Clin Endocrinol Metab       Date:  2005-12-06       Impact factor: 5.958

Review 3.  Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily.

Authors:  Peter I Mackenzie; Karl Walter Bock; Brian Burchell; Chantal Guillemette; Shin-ichi Ikushiro; Takashi Iyanagi; John O Miners; Ida S Owens; Daniel W Nebert
Journal:  Pharmacogenet Genomics       Date:  2005-10       Impact factor: 2.089

Review 4.  UDP-glucuronosyltransferases.

Authors:  C D King; G R Rios; M D Green; T R Tephly
Journal:  Curr Drug Metab       Date:  2000-09       Impact factor: 3.731

Review 5.  The menopause: benefits and risks of estrogen-progestogen replacement therapy.

Authors:  R D Gambrell
Journal:  Fertil Steril       Date:  1982-04       Impact factor: 7.329

6.  The nonfeminizing enantiomer of 17beta-estradiol exerts protective effects in neuronal cultures and a rat model of cerebral ischemia.

Authors:  P S Green; S H Yang; K R Nilsson; A S Kumar; D F Covey; J W Simpkins
Journal:  Endocrinology       Date:  2001-01       Impact factor: 4.736

7.  Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3.

Authors:  Nina Sneitz; Michael H Court; Xiuling Zhang; Kaisa Laajanen; Karen K Yee; Pamela Dalton; Xinxin Ding; Moshe Finel
Journal:  Pharmacogenet Genomics       Date:  2009-12       Impact factor: 2.089

8.  Binding specificity of rat alpha-fetoprotein for a series of estrogen derivatives: studies using equilibrium and nonequilibrium binding techniques.

Authors:  D W Payne; J A Katzenellenbogen
Journal:  Endocrinology       Date:  1979-09       Impact factor: 4.736

9.  Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7.

Authors:  Michael J Miley; Agnieszka K Zielinska; Jeffrey E Keenan; Stacie M Bratton; Anna Radominska-Pandya; Matthew R Redinbo
Journal:  J Mol Biol       Date:  2007-03-30       Impact factor: 5.469

10.  Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6.

Authors:  Mika Kurkela; Anne-Sisko Patana; Peter I Mackenzie; Michael H Court; Christopher G Tate; Jouni Hirvonen; Adrian Goldman; Moshe Finel
Journal:  Pharmacogenet Genomics       Date:  2007-02       Impact factor: 2.089

View more
  8 in total

1.  Neurosteroid analogues. 18. Structure-activity studies of ent-steroid potentiators of γ-aminobutyric acid type A receptors and comparison of their activities with those of alphaxalone and allopregnanolone.

Authors:  Mingxing Qian; Kathiresan Krishnan; Eva Kudova; Ping Li; Brad D Manion; Amanda Taylor; George Elias; Gustav Akk; Alex S Evers; Charles F Zorumski; Steven Mennerick; Douglas F Covey
Journal:  J Med Chem       Date:  2013-12-24       Impact factor: 7.446

2.  The Human UDP-glucuronosyltransferase UGT2A1 and UGT2A2 enzymes are highly active in bile acid glucuronidation.

Authors:  Martin Perreault; Louis Gauthier-Landry; Jocelyn Trottier; Mélanie Verreault; Patrick Caron; Moshe Finel; Olivier Barbier
Journal:  Drug Metab Dispos       Date:  2013-06-11       Impact factor: 3.922

3.  The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study.

Authors:  Moshe Shike; Ashley S Doane; Lianne Russo; Rafael Cabal; Jorge S Reis-Filho; William Gerald; Hiram Cody; Raya Khanin; Jacqueline Bromberg; Larry Norton
Journal:  J Natl Cancer Inst       Date:  2014-09-04       Impact factor: 13.506

4.  The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk.

Authors:  Andrea Y Angstadt; Arthur Berg; Junjia Zhu; Paige Miller; Terryl J Hartman; Samuel M Lesko; Joshua E Muscat; Philip Lazarus; Carla J Gallagher
Journal:  Cancer       Date:  2013-04-10       Impact factor: 6.860

5.  Sexual dimorphism: increased sterol excretion leads to hypocholesterolaemia in female hyperbilirubinaemic Gunn rats.

Authors:  Josif Vidimce; Johara Pillay; Onne Ronda; Ai-Ching Boon; Evan Pennell; Kevin J Ashton; Theo H van Dijk; Karl-Heinz Wagner; Henkjan J Verkade; Andrew C Bulmer
Journal:  J Physiol       Date:  2022-03-01       Impact factor: 6.228

6.  Biotransformation of bisphenol AF to its major glucuronide metabolite reduces estrogenic activity.

Authors:  Ming Li; Yunjia Yang; Yi Yang; Jie Yin; Jing Zhang; Yixing Feng; Bing Shao
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

7.  The Inhibition of the Components from Shengmai Injection towards UDP-Glucuronosyltransferase.

Authors:  Li-Peng Jiang; Jin Zhao; Yun-Feng Cao; Mo Hong; Dong-Xue Sun; Xiao-Yu Sun; Jun Yin; Zhi-Tu Zhu; Zhong-Ze Fang
Journal:  Evid Based Complement Alternat Med       Date:  2014-10-29       Impact factor: 2.629

8.  Impaired liver function in Xenopus tropicalis exposed to benzo[a]pyrene: transcriptomic and metabolic evidence.

Authors:  Christophe Regnault; Isabelle A M Worms; Christine Oger-Desfeux; Christelle MelodeLima; Sylvie Veyrenc; Marie-Laure Bayle; Bruno Combourieu; Aurélie Bonin; Julien Renaud; Muriel Raveton; Stéphane Reynaud
Journal:  BMC Genomics       Date:  2014-08-08       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.